An Immunoperoxidase Monolayer Assay (IPMA) for the detection of lumpy skin disease antibodies

Haegeman, Andy; Leeuw, Ilse De; Mostin, Laurent; Campe, Willem Van; Aerts, Laetitia; Vastag, Mária; Clercq, Kris De

doi:10.1016/j.jviromet.2019.113800

Cited by 36 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Antibodies were earlier detected in the vaccinated animals using IPMA compared to the VNTs, which is in agreement with our previous findings [ 29 ]. A high seroconversion rate was seen with the IPMA, ranging from 71% (Lumpyvax) to 100% (OBP and MCI) at the time of challenge, while this was certainly not the case when using VNTs (0% to 71%).…”

Section: Discussionsupporting

confidence: 93%

“…Sera samples were analyzed using the immunoperoxidase monolayer assay (IPMA) and virus neutralization tests (VNT) as described in Haegeman et al (2020) [ 29 ]. Both VNT methods were applied and are referred to as VNT1 (titration of the test serum against 100TCID 50 of a reference LSDV strain) and VNT2 (titration of an LSDV reference strain against the test serum).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines

et al. 2021

Self Cite

View full text Add to dashboard Cite

Vaccines form the cornerstone of any control, eradication and preventative strategy and this is no different for lumpy skin disease. However, the usefulness of a vaccine is determined by a multiplicity of factors which include stability, efficiency, safety and ease of use, to name a few. Although the vaccination campaign in the Balkans against lumpy skin disease virus (LSDV) was successful and has been implemented with success in the past in other countries, data of vaccine failure have also been reported. It was therefore the purpose of this study to compare five homologous live attenuated LSDV vaccines (LSDV LAV) in a standardized setting. All five LSDV LAVs studied were able to protect against a challenge with virulent LSDV. Aside from small differences in serological responses, important differences were seen in side effects such as a local reaction and a Neethling response upon vaccination between the analyzed vaccines. These observations can have important implications in the applicability in the field for some of these LSDV LAVs.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Methodsmentioning

confidence: 99%

Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ability to count individual foci at different sera dilutions enables endpoint neutralization titers to be determined, but also allows for more discriminating measurements to be made such as the PRNT 50 value which is the concentration of serum to reduce the number of plaques by 50 % compared to the serum free virus. An assay using a peroxidase staining methodology has recently been developed for the detection of both neutralizing and total binding antibodies to LSDV by Immunoperoxidase Monolayer Assay (IPMA) on OA3.T cell lines ( Haegeman et al, 2019 ). Detection of neutralizing antibodies provides information about the function of antibodies present in the sera and can be used to extrapolate levels of protection in the animal, which is the major advantage of the assay over ELISA-based methods for detecting a serological response to LSDV.…”

Section: Discussionmentioning

confidence: 99%

Madin-Darby bovine kidney (MDBK) cells are a suitable cell line for the propagation and study of the bovine poxvirus lumpy skin disease virus

Fay

Cook

Wijesiriwardana

et al. 2020

Journal of Virological Methods

View full text Add to dashboard Cite

Highlights LSDV replicates to high titers (approximately 1 × 10 7 PFU/mL) in MDBK cells. LSDV forms foci-like poxviral plaques in MDBK cells. A plaque-reduction neutralisation test was developed for LSDV antibody quantitation. A method for purification of LSDV genomic DNA was optimized.

show abstract

“…For virus titration assays, Vero/LT cells were seeded at a density of 110, 000 cells/well and (100 μl) of serially diluted virus was added to each well. After an incubation period of 96 h at 37 °C, the virus titer was determined by IPMA assay as described by Andy et al , 2020 [ 30 ].…”

Section: Methodsmentioning

confidence: 99%

Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors

et al. 2021

View full text Add to dashboard Cite

Background Animal vaccination is an important way to stop the spread of diseases causing immense damage to livestock and economic losses and the potential transmission to humans. Therefore effective method for vaccine production using simple and inexpensive bioprocessing solutions is very essential. Conventional culture systems currently in use, tend to be uneconomic in terms of labor and time involved. Besides, they offer a limited surface area for growth of cells. In this study, the CelCradle™-500A was evaluated as an alternative to replace conventional culture systems in use such as Cell factories for the production of viral vaccines against small ruminant morbillivirus (PPR), rift valley fever virus (RVF) and lumpy skin disease virus (LSD). Results Two types of cells Vero and primary Lamb Testis cells were used to produce these viruses. The study was done in 2 phases as a) optimization of cell growth and b) virus cultivation. Vero cells could be grown to significantly higher cell densities of 3.04 × 109 using the CelCradle™-500A with a shorter doubling time as compared to 9.45 × 108 cells in Cell factories. This represents a 19 fold increase in cell numbers as compared to seeding vs only 3.7 fold in Cell factories. LT cells achieved modestly higher cell densities of 6.7 × 108 as compared to 6.3 × 108 in Cell factories. The fold change in densities for these cells was 3 fold in the CelCradle™-500A vs 2.5 fold in Cell factories. The titers in the conventional system and the bioreactor were not significantly different. However, the Cell-specific virus yield for rift valley fever virus and lumpy skin disease virus are higher (25 virions/cell for rift valley fever virus, and 21.9 virions/cell for lumpy skin disease virus versus 19.9 virions/cell for rift valley fever virus and 10 virions/cell for lumpy skin disease virus). Conclusions This work represents a novel study for primary lamb testis cell culture in CellCradle™-500A bioreactors. In addition, on account of the high cell densities obtained and the linear scalability the titers could be further optimized using other culture process such us perfusion.

show abstract

An Immunoperoxidase Monolayer Assay (IPMA) for the detection of lumpy skin disease antibodies

Cited by 36 publications

References 23 publications

Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines

Comparative Evaluation of Lumpy Skin Disease Virus-Based Live Attenuated Vaccines

Madin-Darby bovine kidney (MDBK) cells are a suitable cell line for the propagation and study of the bovine poxvirus lumpy skin disease virus

Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors

Contact Info

Product

Resources

About